Literature DB >> 16611093

Novel treatments of schizophrenia: targeting the neurotensin system.

B Kinkead1, C B Nemeroff.   

Abstract

Evidence implicating neural circuits that utilize the neuropeptide transmitter neurotensin (NT) in the pathophysiology of schizophrenia and in the mechanism of action of antipsychotic drugs has previously been reviewed. The majority of evidence, taken together, supports the development of NT receptor agonists as novel antipsychotic drugs. This review comprehensively describes the NT receptor subtypes, discusses the development of NT receptor agonists and the behavioral effects of currently available NT receptor agonists. The compilation of data suggests that NT receptor agonists may represent a novel class of antipsychotic drugs for the treatment of schizophrenia.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16611093     DOI： 10.2174/187152706776359655

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN： 1871-5273            Impact factor:   4.388


  14 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  Altered gene expression in mice selected for high maternal aggression.

Authors:  S C Gammie; A P Auger; H M Jessen; R J Vanzo; T A Awad; S A Stevenson
Journal:  Genes Brain Behav       Date:  2006-08-29       Impact factor: 3.449

3.  Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity.

Authors:  David Feifel; Zhen Pang; Zheng Pang; Paul D Shilling; Gilia Melendez; Rudy Schreiber; Donald Button
Journal:  Behav Brain Res       Date:  2010-04-21       Impact factor: 3.332

Review 4.  Neurotensin in reward processes.

Authors:  María Luisa Torruella-Suárez; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

5.  The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1).

Authors:  Paolo Di Fruscia; Yuanjun He; Marcel Koenig; Sahba Tabrizifard; Ainhoa Nieto; Patricia H McDonald; Theodore M Kamenecka
Journal:  Bioorg Med Chem Lett       Date:  2014-06-20       Impact factor: 2.823

6.  Antipsychotic-induced gene regulation in multiple brain regions.

Authors:  Matthew James Girgenti; Laura K Nisenbaum; Franklin Bymaster; Rosemarie Terwilliger; Ronald S Duman; Samuel Sathyanesan Newton
Journal:  J Neurochem       Date:  2010-01-13       Impact factor: 5.372

7.  Neurotensin inversely modulates maternal aggression.

Authors:  S C Gammie; K L D'Anna; H Gerstein; S A Stevenson
Journal:  Neuroscience       Date:  2008-12-07       Impact factor: 3.590

8.  Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders.

Authors:  Sarah K Leonard; Jason M Dwyer; Stacey J Sukoff Rizzo; Brian Platt; Sheree F Logue; Sarah J Neal; Jessica E Malberg; Chad E Beyer; Lee E Schechter; Sharon Rosenzweig-Lipson; Robert H Ring
Journal:  Psychopharmacology (Berl)       Date:  2008-03-03       Impact factor: 4.530

9.  Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery.

Authors:  Karin Sterl; Songyan Wang; Lauren Oestricker; Michael J Wallendorf; Bruce W Patterson; Dominic N Reeds; Burton M Wice
Journal:  Peptides       Date:  2016-06-07       Impact factor: 3.750

10.  The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.

Authors:  D Feifel; S Mexal; Gilia Melendez; Philip Y T Liu; Joseph R Goldenberg; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.